HilleVax (HLVX) Competitors

HilleVax (NASDAQ:HLVX) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.

Do analysts rate HLVX or ATYR?

HilleVax presently has a consensus target price of $3.00, suggesting a potential upside of 88.68%. Atyr PHARMA has a consensus target price of $18.60, suggesting a potential upside of 494.25%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts plainly believe Atyr PHARMA is more favorable than HilleVax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HilleVax	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atyr PHARMA	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Is HLVX or ATYR more profitable?

HilleVax's return on equity of -67.27% beat Atyr PHARMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HilleVax	N/A	-67.27%	-51.99%
Atyr PHARMA	N/A	-79.44%	-59.16%

Does the MarketBeat Community prefer HLVX or ATYR?

Atyr PHARMA received 3 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 100.00% of users gave Atyr PHARMA an outperform vote while only 58.82% of users gave HilleVax an outperform vote.

Company	Underperform	Outperform
HilleVax	Outperform Votes 10 58.82%	Underperform Votes 7 41.18%
Atyr PHARMA	Outperform Votes 13 100.00%	Underperform Votes No Votes

Do insiders & institutionals have more ownership in HLVX or ATYR?

86.4% of HilleVax shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 71.1% of HilleVax shares are owned by insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, HLVX or ATYR?

HilleVax has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Which has preferable valuation & earnings, HLVX or ATYR?

Atyr PHARMA has higher revenue and earnings than HilleVax. Atyr PHARMA is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HilleVax	N/A	N/A	-$123.57M	-$3.10	-0.51
Atyr PHARMA	$235K	1,183.53	-$50.39M	-$0.87	-3.60

Does the media favor HLVX or ATYR?

In the previous week, HilleVax and HilleVax both had 4 articles in the media. HilleVax's average media sentiment score of 1.76 beat Atyr PHARMA's score of 0.22 indicating that HilleVax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HilleVax	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Atyr PHARMA	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Atyr PHARMA beats HilleVax on 10 of the 16 factors compared between the two stocks.